Figure 4.
Novel risk stratification scheme for MBGrp3 and MBGrp4 medulloblastoma
(A) Progression-free survival plots for identified risk subgroups (n=156) defined in table 3 and the appendix (p 20). (B) Time-dependent ROC curves at 5 years are shown for this novel risk stratification alongside a published cytogenetic stratification scheme28 (MBGrp4 with chromosome 11 loss or chromosome 17 gain, low risk; MBGrp4 with M– disease, standard risk; MBGrp4 with M+ disease, high risk; MBGrp3 with MYC amplification, i17q, or M+ disease, high risk; MBGrp3 without MYC amplification, i17q, or M+ disease, standard risk), and the PNET5 risk stratification (patients positive for one or more of LCA pathology, M+ disease, R+ disease, MYC(N) amplification are high risk; patients absent for all high-risk features, standard risk), as well as the stratification derived from considering MBGrp3 and MBGrp4 as separate entities (appendix p 22). AUC=area under curve. LCA=large-cell anaplastic. M+=metastatic disease. M–=non-metastatic disease. ROC=receiver operating characteristic.